Stephane Castel Email & Phone Number
@variantbio.com
LinkedIn matched
Who is Stephane Castel? Overview
A concise factual answer block for searchers comparing this professional profile.
Stephane Castel is listed as Co-Founder, Chief Technology Officer at Variant Bio, based in Seattle, Washington, United States. AeroLeads shows a work email signal at variantbio.com and a matched LinkedIn profile for Stephane Castel.
Stephane Castel previously worked as Co-Founder, Chief Technology Officer, Chief Genomics Officer at Variant Bio and Senior Research Fellow at New York Genome Center. Stephane Castel holds Postdoc, Computational Genetics from Columbia University.
Email format at Variant Bio
This section adds company-level context without repeating Stephane Castel's masked contact details.
AeroLeads found 1 current-domain work email signal for Stephane Castel. Compare company email patterns before reaching out.
About Stephane Castel
I co-founded Variant Bio, a biotech startup focused on using the power of human genetic diversity to discover new therapeutics. I was previously a Senior Research Fellow at the New York Genome Center, where I studied the contribution of genetic regulatory variation to disease. Additionally, I co-founded Fiix, a cloud based software company in the asset management space.
Listed skills include Programming, Software Development, Molecular Biology, Statistical Data Analysis, and 2 others.
Stephane Castel's current company
Company context helps verify the profile and gives searchers a useful next step.
Stephane Castel work experience
A career timeline built from the work history available for this profile.
Co-Founder, Chief Technology Officer, Chief Genomics Officer
At Variant Bio I lead the Genomic Discovery Team, which translates health and multi-omics data from studies into novel therapeutic hypotheses.
Senior Research Fellow
Postdoctoral Research Fellow
The vast majority of the human genome is non-coding, and most genome wide association studies (GWAS) have implicated non-coding variants. Methods that integrate the genome and trancsriptome at population scale, such as expression quantitative trait loci (eQTL) and allele specific expression (ASE) studies, have revealed that many non-coding variants affect the expression of nearby genes, providing a potential molecular mechanism underlying their trait association. I have made methodological contributions to both fields and have used these methods to better understand the effects of genetic variation on gene expression, and their contribution to disease. I am a key member of the Analysis Working Group in the Genotype Tissue Expression (GTEx) project, the largest eQTL study to date. In this project, I am responsible for generation and analysis of ASE data, and have performed extensive analyses of eQTL results. This has resulted in a co-lead analyst position on the main GTEx v6 release paper, which was published in Nature. Moving forward, for the final GTEx release I am leading a subgroup aimed at identifying the molecular mechanisms of QTL tissue specificity and am part of the final paper writing group. My most recently published research in Nature Genetics describes how regulatory variation can modify the penetrance of pathogenic coding variants, which we demonstrated using population scale functional genomic data, disease cohorts, and CRISPR-Cas9 experimental validation.
Postdoctoral Research Fellow
Lappalainen LabDepartment of Systems Biology
Graduate Student
Robert Martienssen is a world leader in the field of small RNA silencing and epigenetics. His research group studies a variety of organisms, ranging from economically important Maize (corn) to single celled fission yeast. As a graduate student in Rob’s lab I described a role for small RNA pathways, which classically silence DNA, in maintaining genome stability. When genome stability is compromised there are negative consequences for the cell, which can include cancer in higher organisms.My work in Rob’s lab integrated both high-throughput genomic, and molecular biology experiments. The culmination of my thesis, “Dicer promotes transcription termination at sites of replication stress to maintain genome stability”, involved the analysis of a wide breath of genomic data sets (ChIP-seq, RNA-seq, sRNA-seq) to uncover a novel molecular function for a core component of the RNAi machinery. I performed all analysis for this work personally, and continue to perform analysis for many other members of the lab through ongoing collaborations.
Co-Founder
Fiix Software provides a cloud based computerized maintenance management system (CMMS) for mid to large size enterprises. At its core, a CMMS tracks and schedules maintenance performed on equipment, inventory usage, and personnel time. Fiix has revolutionized the CMMS through ease of use, powerful data analytics, and deployment on mobile platforms. As a co-founder, I was involved with the company through its inception, angel financing, and as an early stage startup. During my time as the Chief Technology Officer I was responsible for designing and developing our core software platform. As Chief Information Officer, I was a driving force behind an analytics-based redesign of our product, and transition to a software as a service (SaaS) cloud-based model. Fiix, which is based out of Toronto, has 170 employees and recently completed a $40 million series C funding round to support further expansion.
Colleagues at Variant Bio
Other employees you can reach at variantbio.com. View company contacts →
Iman Hamid
Colleague at Variant BioIrvine, California, United States
View →
OG
Olivia Gray, Phd
Colleague at Variant BioSeattle, Washington, United States
View →
MA
Mohd Anisul Karim
Colleague at Variant BioSeattle, Washington, United States
View →
LH
Leslie Hepner
Colleague at Variant BioSeattle, Washington, United States
View →
SL
Sarah Lebaron Von Baeyer, Phd
Colleague at Variant BioGreater Boston, United States
View →
MH
Melissa Hendershott
Colleague at Variant BioSeattle, Washington, United States
View →
RH
Ryan Hernandez
Colleague at Variant BioOakland, California, United States
View →
HB
Hiba Babiker
Colleague at Variant BioSeattle, Washington, United States
View →
CS
C. Scott Gallagher
Colleague at Variant BioWashington, District Of Columbia, United States
View →
GP
Gabriel Perez
Colleague at Variant BioKenmore, Washington, United States
View →
Stephane Castel education
Postdoc, Computational Genetics
Ph.D., Genetics
B.Sc.H., Molecular Biology And Genetics
Frequently asked questions about Stephane Castel
Quick answers generated from the profile data available on this page.
What company does Stephane Castel work for?
Stephane Castel works for Variant Bio.
What is Stephane Castel's role at Variant Bio?
Stephane Castel is listed as Co-Founder, Chief Technology Officer at Variant Bio.
What is Stephane Castel's email address?
AeroLeads has found 1 work email signal at @variantbio.com for Stephane Castel at Variant Bio.
Where is Stephane Castel based?
Stephane Castel is based in Seattle, Washington, United States while working with Variant Bio.
What companies has Stephane Castel worked for?
Stephane Castel has worked for Variant Bio, New York Genome Center, Columbia University In The City Of New York, Cold Spring Harbor Laboratory, and Fiix Software.
Who are Stephane Castel's colleagues at Variant Bio?
Stephane Castel's colleagues at Variant Bio include Iman Hamid, Olivia Gray, Phd, Mohd Anisul Karim, Leslie Hepner, and Sarah Lebaron Von Baeyer, Phd.
How can I contact Stephane Castel?
You can use AeroLeads to view verified contact signals for Stephane Castel at Variant Bio, including work email, phone, and LinkedIn data when available.
What schools did Stephane Castel attend?
Stephane Castel holds Postdoc, Computational Genetics from Columbia University.
What skills is Stephane Castel known for?
Stephane Castel is listed with skills including Programming, Software Development, Molecular Biology, Statistical Data Analysis, Technical Writing, and Genomics.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial